Update on Astellas (4503) As It Gets Orphan Drug Status for Gilteritinib
News that gilteritinib has received orphan drug status for acute myeloid leukaemia (AML) would be rather more exciting for Astellas (4503 JP) but...
347 Views
Takeda - Brigantinib Gets FDA Approval
Earlier this year, Takeda Pharmaceutical Co Ltd (4502 JP) spent US$4bil on Ariad Pharmaceuticals Inc (ARIA US), thereby acquiring a company with a...
416 Views
Chugai – Positive Data for Emicizumab from HAVEN 2
After Alecensa impressed in Phase III trials earlier this week, Chugai (4519 JP) had the added pleasure of seeing emicizumab do well in the second...
394 Views
Medrx - Japan Biotech Microcap in Potential Big Licensing Deal
Although the Japanese drug industry suffers from a lack of scale, where it is good is in applying manufacturing techniques to develop not just...
614 Views
Chugai Pharma (4519) - ALEX Trials for Alecensa a Success
Chugai Pharmaceutical (4519 JP) completed the clean sweep on Phase III trials for Alecensa. The latest data, from the ALEX trial, showed its...
223 Views